Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo

10.1182/blood-2007-06-098079

Saved in:

Bibliographic Details
Main Authors:	Nishioka, C, Ikezoe, T, Yang, J, Miwa, A, Tasaka, T, Kuwayama, Y, Togitani, K, Koeffler, H.P, Yokoyama, A
Other Authors:	DEPT OF MEDICINE
Format:	Article
Published:	American Society of Hematology 2020
Subjects:	antineoplastic agent CD135 antigen imatinib ki 11502 mitogen activated protein kinase protein bcl 2 protein kinase B protein tyrosine kinase inhibitor STAT5 protein unclassified drug Ki11502 protein kinase inhibitor protein tyrosine kinase quinoline derivative acute granulocytic leukemia adult aged animal experiment animal model antineoplastic activity apoptosis article cancer inhibition cell cycle arrest cell proliferation cell selection cellular distribution controlled study down regulation drug mechanism female gene mutation human human tissue leukemia leukemia cell male mouse nonhuman priority journal signal transduction animal drug antagonism drug effect mouse mutant pathology treatment outcome tumor cell line xenograft Animals Antineoplastic Agents Apoptosis Cell Line, Tumor Cell Proliferation Humans Leukemia Mice Mice, SCID Protein Kinase Inhibitors Quinolines Receptor Protein-Tyrosine Kinases Transplantation, Heterologous Treatment Outcome
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/183927
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-183927
record_format	dspace
spelling	sg-nus-scholar.10635-1839272023-08-30T22:24:45Z Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo Nishioka, C Ikezoe, T Yang, J Miwa, A Tasaka, T Kuwayama, Y Togitani, K Koeffler, H.P Yokoyama, A DEPT OF MEDICINE antineoplastic agent CD135 antigen imatinib ki 11502 mitogen activated protein kinase protein bcl 2 protein kinase B protein tyrosine kinase inhibitor STAT5 protein unclassified drug antineoplastic agent Ki11502 protein kinase inhibitor protein tyrosine kinase quinoline derivative acute granulocytic leukemia adult aged animal experiment animal model antineoplastic activity apoptosis article cancer inhibition cell cycle arrest cell proliferation cell selection cellular distribution controlled study down regulation drug mechanism female gene mutation human human tissue leukemia leukemia cell male mouse nonhuman priority journal signal transduction animal apoptosis cell proliferation drug antagonism drug effect mouse mutant pathology treatment outcome tumor cell line xenograft Animals Antineoplastic Agents Apoptosis Cell Line, Tumor Cell Proliferation Humans Leukemia Mice Mice, SCID Protein Kinase Inhibitors Quinolines Receptor Protein-Tyrosine Kinases Transplantation, Heterologous Treatment Outcome 10.1182/blood-2007-06-098079 Blood 111 10 5086-5092 2020-11-23T09:02:56Z 2020-11-23T09:02:56Z 2008 Article Nishioka, C, Ikezoe, T, Yang, J, Miwa, A, Tasaka, T, Kuwayama, Y, Togitani, K, Koeffler, H.P, Yokoyama, A (2008). Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood 111 (10) : 5086-5092. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2007-06-098079 0006-4971 https://scholarbank.nus.edu.sg/handle/10635/183927 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ American Society of Hematology Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	antineoplastic agent CD135 antigen imatinib ki 11502 mitogen activated protein kinase protein bcl 2 protein kinase B protein tyrosine kinase inhibitor STAT5 protein unclassified drug antineoplastic agent Ki11502 protein kinase inhibitor protein tyrosine kinase quinoline derivative acute granulocytic leukemia adult aged animal experiment animal model antineoplastic activity apoptosis article cancer inhibition cell cycle arrest cell proliferation cell selection cellular distribution controlled study down regulation drug mechanism female gene mutation human human tissue leukemia leukemia cell male mouse nonhuman priority journal signal transduction animal apoptosis cell proliferation drug antagonism drug effect mouse mutant pathology treatment outcome tumor cell line xenograft Animals Antineoplastic Agents Apoptosis Cell Line, Tumor Cell Proliferation Humans Leukemia Mice Mice, SCID Protein Kinase Inhibitors Quinolines Receptor Protein-Tyrosine Kinases Transplantation, Heterologous Treatment Outcome
spellingShingle	antineoplastic agent CD135 antigen imatinib ki 11502 mitogen activated protein kinase protein bcl 2 protein kinase B protein tyrosine kinase inhibitor STAT5 protein unclassified drug antineoplastic agent Ki11502 protein kinase inhibitor protein tyrosine kinase quinoline derivative acute granulocytic leukemia adult aged animal experiment animal model antineoplastic activity apoptosis article cancer inhibition cell cycle arrest cell proliferation cell selection cellular distribution controlled study down regulation drug mechanism female gene mutation human human tissue leukemia leukemia cell male mouse nonhuman priority journal signal transduction animal apoptosis cell proliferation drug antagonism drug effect mouse mutant pathology treatment outcome tumor cell line xenograft Animals Antineoplastic Agents Apoptosis Cell Line, Tumor Cell Proliferation Humans Leukemia Mice Mice, SCID Protein Kinase Inhibitors Quinolines Receptor Protein-Tyrosine Kinases Transplantation, Heterologous Treatment Outcome Nishioka, C Ikezoe, T Yang, J Miwa, A Tasaka, T Kuwayama, Y Togitani, K Koeffler, H.P Yokoyama, A Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
description	10.1182/blood-2007-06-098079
author2	DEPT OF MEDICINE
author_facet	DEPT OF MEDICINE Nishioka, C Ikezoe, T Yang, J Miwa, A Tasaka, T Kuwayama, Y Togitani, K Koeffler, H.P Yokoyama, A
format	Article
author	Nishioka, C Ikezoe, T Yang, J Miwa, A Tasaka, T Kuwayama, Y Togitani, K Koeffler, H.P Yokoyama, A
author_sort	Nishioka, C
title	Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
title_short	Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
title_full	Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
title_fullStr	Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
title_full_unstemmed	Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
title_sort	kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo
publisher	American Society of Hematology
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/183927
_version_	1779153152253100032

Kill502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo

Similar Items